Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference
March 09, 2022 17:30 ET
|
Immunocore Holdings Limited
Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq:...
Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
March 03, 2022 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Full Year 2021 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp-tebn) approved by the FDA for the treatment of unresectable or metastatic...
Immunocore to present at the SVB Leerink Global Healthcare Conference
February 11, 2022 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the SVB Leerink Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq:...
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4
December 06, 2021 07:00 ET
|
Immunocore Holdings Limited
Immunocore announces initial Phase 1 data of ImmTAC® candidate IMC-C103C targeting MAGE-A4 Clinical activity with confirmed durable responses in ovarian cancer and a confirmed durable...
Immunocore to present at the Jefferies London Healthcare Conference
November 11, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at the Jefferies London Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 November 2021) Immunocore (Nasdaq:...
Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports Third Quarter 2021 Financial Results and Provides Business Update Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions...
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma
September 08, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma MHRA’s...
Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
June 04, 2021 09:05 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology...
Immunocore to present at upcoming investor conferences
May 27, 2021 16:30 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...
Immunocore Reports First Quarter 2021 Financial Results
May 12, 2021 07:00 ET
|
Immunocore Holdings Limited
PRESS RELEASE Immunocore Reports First Quarter 2021 Financial Results Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) is expected to be completed in...